ENTHEON BIOMEDICAL CORP.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED MAY 31, 2026 AND 2025

(Expressed in Canadian Dollars)

(Unaudited)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the condensed interim consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Chartered Professional Accountants of Canada (CPA Canada) for a review of interim financial statements by an entity's auditor.

ENTHEON BIOMEDICAL CORP.
Condensed Interim Consolidated Statements of Financial Position
Expressed in Canadian Dollars (Unaudited)

As at	May 31, 2026	November 30, 2025
	$	$
Assets		
Current assets		
Cash and equivalents	324,308	321,835
Other receivables (Note 6)	178,915	8,552
Prepaid expenses	13,786	18,397
	517,009	348,784
Non-current assets		
Restricted cash	5,000	5,000
	522,009	353,784
Liabilities and shareholders' equity		
Current liabilities		
Accounts payable and accrued liabilities (Note 4)	42,501	29,753
Shareholders' equity		
Share capital (Note 5)	20,608,199	20,608,199
Reserves (Note 5)	24,682	591,013
Deficit	(20,153,373)	(20,875,181)
	479,508	324,031
	522,009	353,784

NATURE OF BUSINESS AND GOING CONCERN (Note 1)

SUBSEQUENT EVENTS (Note 9)

Approved and authorized for issue on behalf of the Board on July 20, 2026:

"Timothy Ko", Director   *"Harrison Newlands"*, Director

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

ENTHEON BIOMEDICAL CORP.
Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Expressed in Canadian Dollars (Unaudited)

	For the three months ended		For the six months ended	
	May 31, 2026	May 31, 2025	May 31, 2026	May 31, 2025
	$	$	$	$
Operating expenses				
Management consulting and payroll	36,205	29,456	60,176	103,289
Office and insurance	6,095	6,971	101,237	55,271
Professional fees	46,755	11,261	10,365	24,759
Transfer agent and filing fees	11,960	18,400	25,438	31,762
Shared-based compensation	-	2,715	-	2,715
	(101,015)	(68,802)	(197,216)	(217,795)
Other income				
Interest income	1,291	2,307	2,693	5,898
Gain on contract termination (Note 6)	350,000	-	350,000	-
	351,291	2,307	352,693	5,898
Net income (loss) and comprehensive income (loss)	255,201	(66,496)	155,477	(211,898)
Net income (loss) per share				
Basic and diluted (Note 8)	$0.02	($0.00)	$0.01	($0.02)
Weighted average number of common shares outstanding	13,858,934	13,858,934	13,858,934	12,952,341

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

ENTHEON BIOMEDICAL CORP.
Condensed Interim Consolidated Statements of Changes in Equity
Expressed in Canadian Dollars (Unaudited)

	Common Shares				
	Number of shares	Amount	Reserves	Deficit	Total
		$	$	$	$
Balance November 30, 2024	8,858,934	20,108,199	961,866	(20,924,737)	145,328
Private placement issuance	5,000,000	500,000	-	-	500,000
Share-based compensation	-	-	2,715	-	2,715
Options expired	-	-	(237,494)	237,494	-
Loss for the period	-	-	-	(211,898)	(211,898)
Balance, May 31, 2025	13,858,934	20,608,199	727,087	(20,899,141)	436,145

	Common Shares				
	Number of shares	Amount	Reserves	Deficit	Total
		$	$	$	$
Balance November 30, 2025	13,858,934	20,608,199	591,013	(20,875,181)	324,031
Options expired	-	-	(566,331)	566,331	-
Income for the period	-	-	-	155,477	155,477
Balance, May 31, 2026	13,858,934	20,608,199	24,682	(20,153,373)	479,508

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

ENTHEON BIOMEDICAL CORP.
Condensed Interim Consolidated Statements of Cash Flows
Expressed in Canadian Dollars (Unaudited)

	For the six months ended	
	May 31, 2026	**May 31, 2025**
	$	**$**
Cash provided by (used in):		
Operating activities		
Net income (loss) and comprehensive income (loss)	155,477	(211,898)
Share-based compensation	-	2,715
Changes in non-cash working capital balance:		
Other receivables	(170,363)	(6,950)
Prepaid expenses	4,611	12,716
Accounts payable and accrued liabilities	12,748	(23,693)
Cash used in operating activities	2,473	(227,110)
Financing activities		
Proceeds from equity financing	-	500,000
Cash provided by financing activities	-	500,000
Increase/(decrease) in cash	2,473	272,890
Cash, beginning of the period	321,835	136,494
Cash and equivalents, end of the period	324,308	409,384
Supplemental cash flow disclosures:		
Income taxes paid	-	-
Interest paid	-	-

The accompanying notes form an integral part of these condensed interim consolidated financial statements.

1. NATURE OF BUSINESS AND GOING CONCERN

Entheon Biomedical Corp. ("Entheon") or ("the Company") was incorporated on April 6, 2010 under the Canadian Business Corporations Act and maintains its head office at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 and registered office at 10th Floor, 595 Howe Street, Vancouver, British Columbia, Canada, V6C 2T5. The Company is traded on the Canadian Securities Exchange ("CSE") under symbol ENBI.

These unaudited condensed interim consolidated financial statements are prepared on a going concern basis, which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. At present, the Company's operations do not generate sufficient cash flow. The Company has incurred losses since inception and had an accumulated deficit of $20,153,373 as at May 31, 2026 (November 30, 2025 - $20,875,181. In order to continue as a going concern and meet its corporate objectives, the Company will require additional financing through debt or equity issuances or other available means. Although the Company has been successful in the past in obtaining financing, there is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. The above factors indicate that material uncertainty exists that cast significant doubt on the Company's ability to continue as a going concern. Should the Company identify a suitable asset or business acquisition, it would be required to raise additional capital to finance the transaction.

These unaudited condensed interim consolidated financial statements do not include adjustments that would be required if the going concern assumption is not an appropriate basis for preparation of the condensed interim consolidated financial statements. These adjustments could be material.

These unaudited condensed interim consolidated financial statements were authorized for issue on July 20, 2026, by the directors of the Company.

2. BASIS OF PREPARATION

These unaudited condensed interim consolidated financial statements have been prepared in accordance with IFRS Accounting Standards, as issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC") which the Canadian Accounting Standards Board has approved for incorporation into Part 1 of the Handbook of Chartered Professional Accountants of Canada applicable to the preparation of interim financial statements, including International Accounting Standard ("IAS") 34, Interim Financial Reporting. These condensed interim consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Company's annual financial statements as at and for the year ended November 30, 2025 and 2024. In particular, the Company's significant accounting policies were summarized in Note 2 of the consolidated financial statements for the year ended November 30, 2025, and have been consistently applied in the preparation of these condensed interim consolidated financial statements. These unaudited condensed interim consolidated financial statements were prepared on a going concern basis.

(Expressed in Canadian dollars)

3. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern.

The Company sets the amount of capital in proportion to risk. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new common shares, sell assets, reduce debt or increase its debt. The capital of the Company comprises the shareholders' equity. The Company is not subject to any externally imposed capital requirements.

4. RELATED PARTY TRANSACTIONS AND BALANCES

Key management personnel comprise the Company's Board of Directors, Chief Executive Officer and Chief Financial Officer. Key management personnel compensation is comprised of the following:

	For the three months ended		For the six months ended	
	May 31, 2026	May 31, 2025	May 31, 2026	May 31, 2025
	$	$	$	$
Payroll, consulting fees, and other benefits	22,665	26,150	57,750	69,650

As at May 31, 2026, $1,154 (November 30, 2025 - $1,154) was due to an officer. The amounts are unsecured, non-interest bearing, due on demand and included in accounts payable and accrued liabilities.

On March 31, 2025, directors received 40,000 stock options that vested immediately and may be exercised for $0.145 to common shares of the Company.

5. SHARE CAPITAL

Authorized

Unlimited number of common shares without par value

Issued and outstanding

As at May 31, 2026, there were 13,858,934 common shares issued and outstanding (November 30, 2025 – 13,858,934).

During the year ended November 30, 2025:

On January 3, 2025, the Company closed a private placement financing for 5,000,000 units ("Unit") for gross proceeds of $500,000. Each Unit is comprised of one common share and one purchase warrant. Each purchase warrant entitles the holder to purchase an additional common share of the Company at $0.15 per share within 24 months of issuance of the Unit. There was no value allocated to the warrants based on the residual method.

(Expressed in Canadian dollars)

5. SHARE CAPITAL (continued)

Stock options

The shareholders of the Company approved a share option plan (the "Options Plan") whereby the Board of Directors may grant to directors, officers, employees and suppliers of the Company share purchase options to acquire common shares of the Company. The terms of each share purchase option are determined by the Board of Directors. Options granted pursuant to the Options Plan shall vest and become exercisable by an optionee at such time or times as may be determined by the Board.

The aggregate number of common shares reserved for issuance pursuant to this Options Plan to all Participants shall not exceed 10% of the issued and outstanding common shares at the time of grant and the maximum number of common shares, which may be reserved for issuance to any optionee, may not exceed 10% of the outstanding common shares at the time of vesting and may not exceed 10% of the outstanding common shares to insiders within a one-year period. These options will expire no later than five years after being granted.

The exercise price per share is established by the Board at the time the option is granted, but, in the event that the common shares are traded on an exchange, the exercise price shall not be less than the closing price of the common shares on the exchange on the trading day immediately preceding the date of the option grant.

A continuity schedule of outstanding share purchase options is as follows:

	Number Outstanding	Weighted Average Exercise Price
		$
Balance, November 30, 2024	140,000	6.28
Issued, March 2025	40,000	0.145
Expired, May 2025	(32,500)	7.10
Balance, November 30, 2025	147,500	4.43
Expired, December 2025	(77,500)	7.10
Balance May 31, 2026	70,000	1.48

As at May 31, 2026, the Company had share purchase options outstanding and exercisable to acquire common shares of the Company as follows:

Grant Date	Expiry Date	Number of options	Exercisable		Exercise Price	Remaining Life
July 29, 2021	July 29, 2026	20,000	20,000	$	3.30	0.16
August 25, 2021	August 25, 2026	10,000	10,000	$	3.20	0.23
March 31, 2025	March 31, 2027	40,000	40,000	$	0.145	0.83
		70,000	70,000	$	1.48	0.56

The share-based compensation from stock options for the three and six months ended May 31, 2026, totalled $nil (three and six months ended May 31, 2025 – $2,715).

On March 31, 2025, the Company granted a total of 40,000 stock options to directors of the Company pursuant to its stock option plan. The options vest immediately and may be exercised at a price of $0.145 per option until March 31, 2027. The fair value of the stock options issued was estimated at $2,715 using the Black-Scholes pricing model using the following assumptions: share price - $0.145; volatility – 260.45%; risk-free interest rate – 2.46%; expected life 2 years and expected dividend yield – 0%.

(Expressed in Canadian dollars)

5. SHARE CAPITAL (continued)

Stock options (continued)

During the six months ended May 31, 2026, 70,000 stock options expired unexercised (year ended November 30, 2025 - 32,500).

Share purchase warrants
A continuity schedule of outstanding share purchase warrants is as follows:

	Number Outstanding	Weighted Average Exercise Price
		$
Balance, November 30, 2024	2,950,000	0.10
Issued	5,000,000	0.15
Balance, November 30, 2025	7,950,000	0.13
Balance, May 31, 2026	7,950,000	0.13

As at May 31, 2026, the Company had the following warrants outstanding:

Grant Date	Expiry Date	Number of warrants	Exercise Price		Remaining life
April 18, 2024	April 18, 2029	2,950,000	$	0.10	2.88
January 5, 2025	January 5, 2027	5,000,000	$	0.15	0.60
		7,950,000	$	0.13	1.45

6. TERMINATION OF CONTRACT

On May 25, 2026, the Company announced that the definitive business combination agreement dated January 19, 2026, as amended on March 9, 2026 ("Business Combination Agreement") between the Company and Nutravisor Inc. ("Nutravisor"), was terminated.

In connection with the termination of the Business Combination Agreement, Nutravisor paid to Entheon a cash termination payment in the amount of $175,000. In addition, Nutravisor has agreed to issue to Entheon such number of common shares of Nutravisor, or of the resulting issuer in connection with a go-public transaction, as has an aggregate deemed value of $175,000 ("Settlement Shares"), calculated based on a deemed issue price per Settlement Share equal to the greater of: (a) CAD $0.50 per share; and (b) 80% of the price per common share issued, sold or deemed issued in connection with Nutravisor's next liquidity event.

7. FINANCIAL INSTRUMENTS

Fair Values and Classification

The Company's financial instruments consist of cash and restricted cash, and accounts payable. Financial instruments are classified into one of the following categories: FVTPL, FVTOCI, or amortized cost. The carrying values of the Company's financial instruments are classified into the following categories:

Financial Instrument	Category		May 31, 2026		November 30, 2025
Cash, equivalents and restricted cash	FVTPL	$	329,308	$	326,835
Other receivables	FVTPL		175,000		175,000
Accounts payable	Amortized cost		1,145		2,201

7. FINANCIAL INSTRUMENTS (continued)

IFRS 9 Financial Instruments: Disclosures establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value as follows:

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Cash and equivalents and restricted cash of $329,308 is recorded at fair value and classified as level 1. Other receivables is recorded as a level 3 financial instrument. The carrying amounts of the Company's accounts payable are a reasonable approximation of their fair values based on current market rates for similar financial instruments.

Within Level 3, the Company includes private company investments that are not quoted on an exchange. The key assumptions used in the valuation of these instruments include (but are not limited to) the value at which a recent financing was done by the investee, company-specific information, trends in general market conditions and the share performance of comparable publicly-traded companies.

As valuations of investments for which market quotations are not readily available, are inherently uncertain, may fluctuate within short periods of time and are based on estimates, determination of fair value may differ materially from the values that would have resulted if a ready market existed for the investments. Given the size of the private investment portfolio, such changes may have a significant impact on the Company's financial condition or operating results.

As at May 31, 2026, a +/- 10% change in the fair value of Nutravisor will result in a corresponding +/- $17,500 change in the carrying amount. While this illustrates the overall effect of changing the values of the unobservable inputs by a set percentage, the significance of the impact and the range of reasonably possible alternative assumptions may differ significantly between investments, given their different terms and circumstances. The sensitivity analysis is intended to reflect the significant uncertainty inherent in the valuation of private investments under current market conditions, and the results cannot be extrapolated due to non-linear effects that changes in valuation assumptions may have on the estimated fair value of these investments. Furthermore, the analysis does not indicate a probability of changes occurring and it does not necessarily represent the Company's view of expected future changes in the fair value of these investments. Any management actions that may be taken to mitigate the inherent risks are not reflected in this analysis.

Financial instrument risk exposure

The Company's financial instruments are exposed to certain financial risks, including credit risk, liquidity risk, and market risk.

(a) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company has exposure to credit risk through its cash and cash equivalents. The Company manages credit risk, in respect of cash, by maintaining the majority of cash at highly rated financial institutions.

The Company's maximum exposure to credit risk at the end of any period is equal to the carrying amount of these financial assets as recorded in the statement of financial position. At May 31, 2026 and December 31, 2025, no amounts were held as collateral.

(Expressed in Canadian dollars)

7. FINANCIAL INSTRUMENTS (continued)

(b) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows required by its operating, investing and financing activities. The Company had cash and equivalents at May 31, 2026, in the amount of $324,308 and working capital of $474,508 in order to meet short-term business requirements. Accounts payable have contractual maturities of approximately 30 to 90 days or are due on demand and are subject to normal trade terms.

The maturity profiles of the Company's contractual obligations and commitments as at May 31, 2026, are summarized as follows:

	Total	Less Than 1 Year	1-5 Years	More Than 5 Years
Accounts payable	$ 42,501	$ 42,501	$ -	$ -
Total	$ 42,501	$ 42,501	$ -	$ -

(c) Market Risk

Market risk consists of interest rate risk, foreign currency risk and price risk. These are discussed further below.

Interest Rate Risk

Interest rate risk consists of two components:

(i) To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk.

(ii) To the extent that changes in prevailing market rates differ from the interest rates on the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

In management's opinion, the Company is not exposed to significant interest rate risk as the risk is primarily on cash and cash equivalents.

Foreign Currency Risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is not subject to significant foreign exchange risk.

Price Risk

Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices, other than those arising from interest rate risk or foreign currency risk.

The Company is exposed not exposed to any significant price risk.

(Expressed in Canadian dollars)

8. EARNINGS PER SHARE

Basic and diluted earnings (loss) per share were calculated using the following weighted average number of common shares outstanding:

	Three months ended		Six months ended	
	May 31, 2026	**May 31, 2025**	**May 31, 2026**	**May 31, 2025**
Net income (loss) attributable to common shareholders ($)	255,201	(66,496)	155,477	(211,898)
Weighted average number of common shares (basic)	13,858,934	13,858,934	13,858,934	12,952,341
Basic earnings (loss) per share ($)	0.02	(0.00)	0.01	(0.02)
Effect of dilutive share options and warrants	-	-	-	-
Weighted average number of common shares (diluted)	13,858,934	13,858,934	13,858,934	12,952,341
Diluted earnings (loss) per share ($)	0.02	(0.00)	0.01	(0.02)

The following potentially dilutive securities were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the three and six months ended May 31, 2026, the exercise prices of these instruments exceeded the average market price of the Company's common shares during the respective periods. For the comparative periods ended May 31, 2025, the Company reported a net loss and, accordingly, all potentially dilutive securities were excluded from diluted earnings per share as their effect would have been anti-dilutive.

	May 31, 2026	**May 31, 2025**
Stock options	70,000	127,500
Warrants	7,950,000	7,950,000

9. SUBSEQUENT EVENT

Subsequent to May 31, 2026, 20,000 options expired unexercised.